Author:
Takahashi Masaya,Takahashi Katsuyuki,Ogawa Kazuki,Takashima Tsutomu,Asano Yuka,Kashiwagi Shinichiro,Noda Satoru,Onoda Naoyoshi,Ohira Masaichi,Nagayama Katsuya
Publisher
Springer Science and Business Media LLC
Reference28 articles.
1. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR, Infectious Diseases Society of America (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52:e56–e93.
https://doi.org/10.1093/cid/cir073
2. National Comprehensive Cancer Network. NCCN Clinical practice guidelines in oncology prevention and treatment of cancer-related infections version 1.2018.
https://www.nccn.org/professionals/physician_gls/pdf/infections.pdf
. Accessed 3 May 2018
3. Kimura K, Tanaka S, Iwamoto M, Fujioka H, Sato N, Terasawa R, Kawaguchi K, Matsuda J, Umezaki N, Uchiyama K (2016) Outpatient management without initial assessment for febrile patients undergoing adjuvant chemotherapy for breast cancer. Mol Clin Oncol 5:385–390.
https://doi.org/10.3892/mco.2016.992
4. Niho S, Ohe Y, Goto K, Ohmatsu H, Matsumoto T, Kubota K, Kakinuma R, Nishiwaki Y (2004) Randomized trial of oral versus intravenous antibiotics in low-risk febrile neutropenic patients with lung cancer. Jpn J Clin Oncol 34:69–73.
https://doi.org/10.1093/jjco/hyh019
5. Kern WV, Marchetti O, Drgona L, Akan H, Aoun M, Akova M, de Bock R, Paesmans M, Viscoli C, Calandra T (2013) Oral antibiotics for fever in low-risk neutropenic patients with cancer: a double-blind, randomized, multicenter trial comparing single daily moxifloxacin with twice daily ciprofloxacin plus amoxicillin/clavulanic acid combination therapy—EORTC infectious. J Clin Oncol 31:1149–1156.
https://doi.org/10.1200/JCO.2012.45.8109